Marc Vimolratana

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/58a00310-6a8c-11ec-afc2-e529147b8d1e.jpg

First Name

Marc

Last Name

Vimolratana

NPI

1467870683

Faculty ID

17157

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

163553

Biography

<p>Marc Vimolratana, MD, MS, is Assistant Professor, Cardiothoracic and Vascular Surgery at Montefiore Einstein. Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases. Dr. Vimolratana takes a patient-centered approach to patient care and is committed to using minimally invasive techniques, including VATS and robotic surgery, whenever possible to minimize surgical trauma and pain for patients.</p><p>Dr. Vimolratana studied chemistry at Yale, earning a Bachelor of Science and Master of Science in 2006. He attended medical school at the University of California, San Francisco, earning a Doctor of Medicine in 2014. After many years in California, he moved to New York for postdoctoral training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he completed a residency in general surgery in 2019, serving as chief resident in his final year. Dr. Vimolratana continued at NewYork-Presbyterian Hospital for fellowship training in cardiothoracic surgery prior to joining the faculty at Montefiore Einstein in 2021.</p><p>Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.</p><p>Dr. Vimolratana is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He is a member of several professional organizations, including the American College of Surgeons, the Society of Thoracic Surgeons and the European Society of Thoracic Surgeons. He has been honored with numerous awards for academic excellence and clinical care.</p>

Is Open Scheduling

Off

Brendon M. Stiles

https://assets.montefioreeinstein.org/profiles/images/Stiles_Brendon_MD_2x.jpg

First Name

Brendon

Last Name

Stiles

NPI

1013176387

Faculty ID

16884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNoSpacing">Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein.&nbsp; Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p>
<p class="MsoNoSpacing">Dr. Stiles is also heavily involved with translational and basic research.&nbsp; Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.&nbsp; &nbsp;In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation.&nbsp;</p>
<p class="MsoNoSpacing">Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.&nbsp; Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.<span style="mso-spacerun: yes;">&nbsp; </span>ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.</p>
<p class="MsoNoSpacing"><span style="font-size: 12pt;">Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.</span></p>
<p class="MsoNoSpacing">&nbsp;</p>
<p class="MsoNoSpacing">&nbsp;</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif;">Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.&nbsp;&nbsp;<em>Science Translational Medicine.&nbsp;</em>2022 Mar 16;14(636):eabe8195.&nbsp;&nbsp;</span><u style="font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 14px;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis."&nbsp;</span><em style="font-size: 12pt;"><span style="font-family: Arial, sans-serif;">Nature Reviews Cancer</span></em><span style="font-size: 12pt;">&nbsp;19.1 (2019): 9-31.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Yao, Zhan, et al. "TGF-&beta; IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Proceedings of the National Academy of Sciences</span></em>&nbsp;107.35 (2010): 15535-15540.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Cancer research</span></em>&nbsp;72.6 (2012): 1384-1394.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">The Lancet Oncology</span></em>&nbsp;22.6 (2021): 824-835.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">JOURNAL FOR IMMUNOTHERAPY OF CANCER</span></em>. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Journal of Thoracic Oncology</span></em>&nbsp;11.2 (2016): S44.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">https://scholar.google.com/citations?user=fR4OkgkAAAAJ&amp;hl=en&amp;oi…;

EMR ID

82842

Biography

<p>Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p><p>&ldquo;The recruitment of&nbsp;Dr. Stiles elevates the treatment of lung cancer to a historic level,&rdquo; said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein. &ldquo;Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.&rdquo;</p><p>After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.&nbsp; He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.</p><p>Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.</p><p>Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.&nbsp; Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.</p>

Is Open Scheduling

Off

Neel P. Chudgar

https://assets.montefioreeinstein.org/profiles/images/Chudgar_Neel_MD_2x.jpg

First Name

Neel

Last Name

Chudgar

NPI

1598022709

Faculty ID

17032

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;">Dr. Chudgar is a thoracic surgeon with a special interest in the treatment of lung and esophageal cancer, as well as malignancies of the mediastinum and chest wall. He is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up.&nbsp;</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="background-color:#ffffff;">Dr. Chudgar&nbsp;</span><span style="color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;">is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up. He also has an interest in the biology of early-stage lung cancer to aid in earlier detection.&nbsp;</span>

Elsevier Profile

EMR ID

163558

Biography

<p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Neel P. Chudgar, MD, is Associate Director of Clinical and Translational Research, Thoracic Surgery, and an Attending Physician at Montefiore. He is also an Assistant Professor of Cardiothoracic and Vascular Surgery at our Albert Einstein College of Medicine.&nbsp;</span></p><p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-top:2rem;margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Dr. Chudgar received his Bachelor of Arts from Boston University in 2008 and earned his Doctor of Medicine from Renaissance School of Medicine at Stony Brook University in 2012. His postdoctoral training began with a General Surgery residency at NewYork-Presbyterian Hospital, Weill Cornell Medical Center. From 2014 to 2016, he was a research fellow with Memorial Sloan Kettering Cancer Center. In 2021, he completed his Cardiothoracic Surgery fellowship with NewYork-Presbyterian, Weill Cornell and Memorial Sloan Kettering Cancer Center.</span></p><p style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);margin-top:2rem;margin-bottom:0px;color:#313335;font-family:'Leitura News', Georgia, Cambria, 'Times New Roman', Times, serif;font-size:medium;background-color:#ffffff;"><span style="box-sizing:border-box;border:0px solid rgb(226, 232, 240);">Dr. Chudgar is a thoracic surgeon with a special interest in the treatment of lung and esophageal cancer, as well as malignancies of the mediastinum and chest wall. He is involved in the investigation of incidental lung nodules to ensure potential lung cancers are not lost to follow-up. He also has an interest in the biology of early-stage lung cancer to aid in earlier detection. He is board certified and his work has been shared in many peer-reviewed publications, book chapters and oral presentations.</span></p>

Is Open Scheduling

Off